Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma LSE:MTPH London Ordinary Share GB00BRTL9B63 ORD 0.005P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +4.88% 5.375p 5.25p 5.50p 5.375p 5.125p 5.125p 442,029 14:31:51
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.8 -17.3 -31.0 - 3.29

Midatech Pharma Share Discussion Threads

Showing 426 to 449 of 450 messages
Chat Pages: 18  17  16  15  14  13  12  11  10  9  8  7  Older
DateSubjectAuthorDiscuss
13/1/2019
20:41
Have a listen especially at the end they want to keep the Nasdaq listing hxxp://www.midatechpharma.com/audio/180928%20Midatech%20Pharma.mp3
hope67
13/1/2019
20:39
hxxps://www.proac tiveinvestors.co.uk/companies/news/203950/big-names-in-pharma-starting-to-take-note-of-midatech-pharma-s-drug-delivery-technology-203950.html
hope67
13/1/2019
20:36
hxxp://www.midatechpharma.com/uploads/investor_files/180927%20Interims%20September%202018%20Final.pdf
hope67
11/1/2019
20:12
Worth a read htxp://www.evaluate.com/vantage/articles/interviews/midatech-hopes-find-golden-touch-new-focus
hope67
11/1/2019
20:11
Look at the volume on the 10th in the Us hxxp://www.stockhouse.com/companies/quote?symbol=mtp
hope67
11/1/2019
20:10
1 November 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") NASDAQ Minimum Bid Price Extension Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, announces that, as previously disclosed, on 1 May, 2018, Midatech Pharma PLC (the "Company") received a letter ("Notification Letter") from The Nasdaq Stock Market LLC ("NASDAQ") providing notification that, for the previous 30 consecutive business days, the bid price for the Company's American Depositary Shares had closed below the minimum $1.00 bid price per share requirement for continued listing on The NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). Each American Depositary Share represents two ordinary shares of the Company. On 30 October 2018, the Company was notified by NASDAQ that its American Depositary Shares have not regained the minimum $1.00 bid price per share requirement within the 180 calendar days following receipt of the Notification Letter. However, NASDAQ has determined that the Company is eligible for an additional 180 calendar day period, pursuant to NASDAQ Listing Rule 5810(c)(3)(A), or until 29 April 2019, to regain the minimum $1.00 bid price per share requirement. This will be met if, at any time during this 180 days period, the closing bid price of the Company's American Depositary Shares is at least $1.00 for a minimum of ten consecutive business days.
hope67
10/1/2019
15:55
250k in at 6.5p - There is a BUYER and SELLER here -
tomboyb
10/1/2019
15:53
6.49p is ask now -
tomboyb
10/1/2019
15:14
Rake - Looks like NOBBY is correct - Nobbygnome10 Jan '19 - 13:13 - 233 of 238 0 2 0 tomboy I think you are wrong in your comparison of prices. One ADS is equivalent to 2 shares on AIM so the price should be around 8p based on the US price.
tomboyb
10/1/2019
14:37
Current price is 0.20c which equates to around 16 pence
rakepat37
10/1/2019
14:27
Lets see what the market over at U.S makes of the news today - Selling at 6.75p when the market across the pond is around 8pish mark - Will look to add further on any weakness -
tomboyb
10/1/2019
13:52
Check out the 5 dollers price target http://s1.q4cdn.com/460208960/files/News/2018/Zacks_SCR_Research_10032018_MTP_Bautz.pdf
rakepat37
10/1/2019
13:38
yes I see now. thanks.
babbler
10/1/2019
13:19
Nobby - Thanks - If u see my previous posts i was asking the question of that discrepancy - We are still below that share price (which is why i said i could not understand it and went in blindly at 6.25p) -
tomboyb
10/1/2019
13:13
tomboy I think you are wrong in your comparison of prices. One ADS is equivalent to 2 shares on AIM so the price should be around 8p based on the US price.
nobbygnome
10/1/2019
12:36
Check out @portefeuillefun's Tweet: https://twitter.com/portefeuillefun/status/1083340718691762177?s=09
aba978731dom
10/1/2019
12:34
Back into ths 8p range here - Discrepancy is massive - It should certainly not be so - Which begs the question of MARKET MAKERS and arbitrage -
tomboyb
10/1/2019
12:33
And now fully funded ... time to catch up to 16p
rakepat37
10/1/2019
12:20
convert it from dollars to GBP. What does the price equate to? Either a massive fall there or we need to catch up.
babbler
10/1/2019
12:14
Look at the price it's worth 16p
rakepat37
10/1/2019
12:07
What am i missing here. When I look at the nasdaq chart it shows 16% rise not the 100% people are talking about....
pilkersa
10/1/2019
12:03
Well I bought on the shake. us open soon...
babbler
10/1/2019
11:30
Idiotic punters are helping the MMs out by bailing out. Make their pips squeak!
nobbygnome
10/1/2019
10:49
OT) Please look at Futura Medical (FUM) has a dirt low market cap of 22 Million and 3 Drugs including a potential MEGA Blockbuster in Phase 3 trial which is light years better than Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM Research Confirms MED2002's US$1 Billion Potential hxxps://futuramedical.com/content/news/archive17/060317b.asp The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time. Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide. Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life. The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development. The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action. The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts. Pipeline hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp first patient dosed: in Q3/Q4 2018 Last patient dosed: by end of June 2019 Headline efficacy results: by end of December 2019 CSD500: Erectogenic condom hxxps://futuramedical.com/content/products/csd_500.asp Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets. Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018. Out-licensing discussions for TPR100 outside of the UK are ongoing.
bioking
Chat Pages: 18  17  16  15  14  13  12  11  10  9  8  7  Older
Your Recent History
LSE
MTPH
Midatech P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190121 05:23:33